European Medicines Agency Recommends Approval for Two Boehringer Ingelheim Avian Flu Vaccines
Key Insights
The European Medicines Agency (search)'s Committee for Veterinary Medicinal Products (search) has issued positive opinions for Boehringer Ingelheim's Vaxxitek HVT+IBD+H5 (search) and Vaxxinact H5 (search) vaccines targeting the H5 avian influenza (search) strain.
Vaxxitek HVT+IBD+H5 (search) represents the first trivalent vaccine offering combined protection against Marek's disease (search), Infectious Bursal Disease (search), and H5 avian influenza (search) in a single shot for chickens and turkeys.
Both vaccines feature DIVA technology that includes biomarkers to distinguish vaccination immune responses from infection antibodies, supporting surveillance efforts and reducing trade restrictions.
The European Medicines Agency (search)'s Committee for Veterinary Medicinal Products (search) (CVMP) has adopted positive opinions for two Boehringer Ingelheim vaccines targeting the highly pathogenic H5 avian influenza (search) virus, marking a significant step toward enhanced outbreak preparedness in Europe.
The CVMP has recommended European Union marketing authorization under exceptional circumstances for Vaxxitek HVT+IBD+H5 (search) and Vaxxinact H5 (search), both designed to immunize birds against the H5 strain that is currently causing outbreaks across Europe and globally.
Innovative Vaccine Technologies
Vaxxitek HVT+IBD+H5 (search) represents a breakthrough as the first trivalent vaccine offering combined protection against Marek's disease (search), Infectious Bursal Disease (search), and H5 avian influenza (search) in chickens and turkeys in one single shot. Vaxxinact H5 (search) is an inactivated vaccine that protects chickens, turkeys, and ducks against avian influenza (search) H5 virus (search) subtype.
Both vaccines incorporate DIVA (Differentiate Infected from Vaccinated Animals) technology, featuring biomarkers that distinguish the immune response to vaccination from antibodies caused by infection. This capability enables surveillance programs to differentiate between vaccinated and infected animals, supporting safe trade while maintaining vaccination protocols.
"By continuously monitoring the efficacy of our vaccines and advancing our technologies, we ensure the right protection against the evolving avian influenza (search) virus," said Taoufik Rawi, head of franchise and poultry for Boehringer Ingelheim. "The positive opinions for Vaxxitek HVT+IBD+H5 (search) and Vaxxinact H5 (search) are critical to increase preparedness against avian influenza outbreaks in Europe."
Global Impact and Economic Significance
Since 2021, highly pathogenic avian influenza (search) H5 has caused unprecedented outbreaks, spreading across most continents globally and leading to massive poultry losses. The outbreaks have expanded to new regions including Latin America and Antarctica, with highly pathogenic avian influenza detected in Europe and Canada in 2021 before reaching the United States through seasonal migration of wild birds.
The economic impact has been severe, with tremendous financial damage to the poultry industry, disruptions in egg and poultry meat availability, and trade restrictions. Millions of poultry have been affected throughout the United States, with recent outbreaks reported in Iowa, Minnesota, and Wisconsin. Nebraska recently reported its first case of H5N1 (search) in dairy cattle after the virus was detected in milk samples.
Regulatory Pathway and Industry Support
The World Organisation for Animal Health (search) has advised that vaccination for avian influenza (search) may be recommended under certain conditions, suggesting that vaccination should be integrated into comprehensive disease control strategies. However, decisions on vaccination against avian influenza rest with each country's veterinary authority.
"Transboundary animal diseases like avian influenza (search) will continue to be a threat, so new approaches to control these infectious diseases in animals, especially livestock, are increasingly important," said Armin Wiesler, head of the animal health business unit and member of the board of managing directors for Boehringer Ingelheim. The company is ready to support governments, health authorities, and producers with its vaccines and provide expertise for monitoring and setting up disease control plans.
Following the CVMP's positive opinions, the European Commission is expected to decide on marketing authorizations under exceptional circumstances in the coming months. These vaccines could play an important role in monitoring disease outbreaks and, when combined with surveillance, can help reduce the risk of trade restrictions for animal products.